The peptide CDMO (contract development and manufacturing organization) market is booming. More companies need peptides made, but there are not enough manufacturers to go around.
This is creating big changes in the contract manufacturing world. Let us look at what is happening and what it means for drug developers.
- Peptide CDMO demand is surging because building in-house GMP facilities costs 200 to 500 million dollars and takes years.
- A global capacity shortage means wait times for CDMO slots now stretch 12 to 18 months or longer.
- Market consolidation is accelerating as large CDMOs acquire smaller firms to expand capacity and capabilities.
- Lock in longer-term CDMO partnerships early to secure manufacturing slots before capacity tightens further.
- Evaluate CDMOs on technology upgrades like continuous flow synthesis and automation, not just current capacity.
- The workforce shortage in peptide manufacturing is a critical bottleneck that CDMOs and clients must plan around.
What Is a Peptide CDMO?
A CDMO is a company that makes drugs for other companies. The "C" stands for contract, meaning they do the work under an agreement with a drug developer.
A peptide CDMO specializes in making peptide drugs. They handle everything from development to large-scale manufacturing under GMP (Good Manufacturing Practice) conditions.
Many drug companies prefer to outsource their peptide manufacturing to CDMOs instead of building their own facilities. This saves time and money.
Why the Peptide CDMO Market Is Growing
Exploding Demand for Peptide Drugs
The success of GLP-1 drugs has created enormous demand for peptide manufacturing. Drug companies need billions of doses produced every year.
Most drug companies do not have the capacity to make this much peptide in-house. They turn to CDMOs to fill the gap.
More Peptides in Clinical Trials
The number of peptide drug candidates in clinical trials has doubled in the past five years. Each of these candidates needs manufacturing support.
According to Roots Analysis, there are over 150 peptide drugs in active clinical development worldwide. This creates sustained demand for CDMO services across all phases of development.
High Cost of Building In-House
Building a GMP peptide manufacturing facility costs hundreds of millions of dollars. It takes 3-5 years to complete.
For many companies, especially startups and mid-size biotechs, outsourcing to a CDMO is the only practical option.
The average cost to build a new GMP peptide manufacturing facility is between 200 and 500 million dollars. This is why most companies prefer to use CDMOs.
Global peptide CDMO capacity utilization now exceeds 85%, meaning most contract manufacturers are running near their production limits with little room to absorb new clients.
Current Peptide CDMO Market Landscape
Major Players
The peptide CDMO market is dominated by a few large players.
| Company | Headquarters | Key Capabilities |
|---|---|---|
| Bachem | Switzerland | Full-service peptide CDMO, largest globally |
| Polypeptide Group | Sweden/Denmark | Large-scale peptide manufacturing |
| AmbioPharm | USA | Cost-competitive peptide manufacturing |
| Thermo Fisher Scientific | USA | Integrated pharma services including peptides |
| CordenPharma | International | Multi-site peptide manufacturing network |
These companies handle a large share of the global peptide CDMO market. But even they are struggling to keep up with demand.
Capacity Shortage
The biggest issue in the peptide CDMO market right now is capacity. There is simply not enough manufacturing capacity to meet the growing demand.
Wait times for new projects have increased significantly. Some CDMOs are quoting lead times of 12-18 months for new GMP manufacturing projects.
Geographic Distribution
Most peptide CDMO capacity is concentrated in Europe and North America. However, capacity is growing in Asia, particularly in India and China.
Asian CDMOs are attracting clients with lower costs and faster timelines.
Key Trends in the Peptide CDMO Market
Consolidation
Larger CDMOs are acquiring smaller ones to increase capacity and capability. This consolidation trend is expected to continue.
Private equity firms are driving much of this activity. They see the peptide CDMO space as a high-growth investment opportunity.
Capacity Expansion
Major CDMOs are investing heavily in new facilities and equipment. Bachem, for example, has announced multiple expansion projects to increase its peptide manufacturing capacity.
These expansions take years to complete, so the capacity shortage will continue in the near term.
Technology Upgrades
CDMOs are investing in new manufacturing technologies to improve efficiency. Continuous flow synthesis, automation, and AI-driven process optimization are all being adopted.
These technologies help CDMOs produce more peptide with the same equipment, partially addressing the capacity shortage.
Longer-Term Partnerships
Drug companies are moving away from project-by-project outsourcing. Instead, they are forming long-term strategic partnerships with their CDMOs.
These partnerships guarantee capacity and provide more stability for both parties. They are becoming the preferred model in the industry.
Specialization
Some CDMOs are specializing in specific types of peptide manufacturing. This includes complex peptides, peptide-drug conjugates, or large-scale commercial production.
Specialization allows CDMOs to build deep expertise and offer better service in their focus areas.
How to Choose a Peptide CDMO
Choosing the right CDMO is one of the most important decisions a drug developer can make. Here are the key factors to consider.
- Track record. Has the CDMO successfully manufactured peptides at the scale you need?
- Regulatory compliance. Does the CDMO have current GMP certifications from relevant regulatory agencies?
- Capacity. Can the CDMO deliver on your timeline, including future scale-up needs?
- Technology. Does the CDMO use modern manufacturing technologies?
- Location. Is the CDMO in a location that works for your supply chain and regulatory needs?
- Communication. Does the CDMO communicate clearly and respond quickly to issues?
- Financial stability. Is the CDMO financially stable and likely to be around long-term?
Learn more about outsourcing your peptide manufacturing to make the best choice.
Start CDMO discussions 18 to 24 months before you need commercial supply, and negotiate capacity reservation clauses in your contracts so you are not stuck waiting when demand spikes.
Impact on Drug Development Timelines
The CDMO capacity shortage is affecting drug development timelines. Companies that cannot secure manufacturing capacity may face delays in their clinical programs.
Here are some strategies to manage this risk.
- Start early. Engage with CDMOs well before you need manufacturing. Do not wait until the last minute.
- Build relationships. Long-term partnerships give you priority access to capacity.
- Consider multiple CDMOs. Having backup manufacturing options reduces risk.
- Plan for scale-up. Think about commercial manufacturing needs during early development, not after.
Pricing Trends
Peptide CDMO pricing has been increasing due to the capacity shortage. Here is what is happening.
The supply-demand imbalance has given CDMOs more pricing power. Prices for GMP peptide manufacturing have increased by an estimated 15-25 percent over the past two years.
However, competition from Asian CDMOs is putting some downward pressure on pricing. Companies willing to work with Asian manufacturers can often find lower costs.
The Workforce Challenge
CDMOs need skilled people to operate their facilities. The workforce shortage in the peptide industry affects CDMOs just as much as drug developers.
Key roles that CDMOs struggle to fill include:
- Peptide synthesis chemists
- Analytical scientists
- Quality assurance and quality control specialists
- Manufacturing operators
- Process development scientists
Learn about how peptide staffing solutions can help CDMOs find the talent they need.
"The peptide CDMO market is at an inflection point. Demand is growing faster than capacity, and the companies that invest in expansion now will be the winners of the next decade." - Dr. Karen Liu, Pharmaceutical Outsourcing Analyst
The Future of Peptide CDMOs
More Automation
CDMOs will invest in automation to increase throughput and reduce labor costs. Robotic systems for peptide synthesis and purification are already being deployed.
AI-Driven Manufacturing
AI will help CDMOs optimize their processes, predict equipment maintenance needs, and improve quality control. This will increase efficiency and reduce costs.
Modular Manufacturing
Modular manufacturing facilities can be built faster and more cheaply than traditional plants. Some CDMOs are exploring this approach to add capacity more quickly.
Vertical Integration
Some drug companies may decide to build their own peptide manufacturing capabilities rather than relying entirely on CDMOs. This could change the competitive dynamics of the market.
Frequently Asked Questions
What is a peptide CDMO?
A peptide CDMO is a contract development and manufacturing organization that specializes in making peptide drugs for other companies under GMP conditions.
Why is the peptide CDMO market growing?
The market is growing because of exploding demand for peptide drugs (especially GLP-1 drugs), more peptides in clinical trials, and the high cost of building in-house manufacturing.
Is there a shortage of peptide manufacturing capacity?
Yes. Demand for peptide manufacturing exceeds available capacity. Wait times for new projects at many CDMOs are 12-18 months or longer.
How much does peptide CDMO manufacturing cost?
Costs vary widely based on the peptide complexity, scale, and purity requirements. GMP manufacturing prices have increased 15-25 percent in recent years due to demand.
Which are the largest peptide CDMOs?
Bachem, Polypeptide Group, AmbioPharm, Thermo Fisher Scientific, and CordenPharma are among the largest peptide CDMOs in the world.
How do I choose a peptide CDMO?
Key factors include track record, regulatory compliance, available capacity, technology, location, communication quality, and financial stability.
Will the capacity shortage end soon?
Major CDMOs are investing in expansion, but new facilities take years to build. The shortage is expected to continue through at least 2028.
Topics
Amanda Foster
Peptide Industry Analyst
MS, Health Economics | 8 years in peptide market research
Tracks workforce trends, compensation data, and market dynamics across the peptide industry. Produces quarterly salary benchmarks and employer-of-record analysis cited by clinic operators nationwide.
Reviewed by Amanda Foster, MS, April 2026